Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marshall Mazepa

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
American Journal of Hematology|September 23, 2023
Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance databaseNattawat Klomjit, Richard Evans, Thomas K Le, et al.
Platelets|November 29, 2017
Endothelial alterations in a canine model of immune thrombocytopeniaDana N LeVine, Rachel E Cianciolo, Keith E Linder, et al.
Journal of the American Academy of Dermatology|August 30, 2022
Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyriaAmy K Dickey, Hetanshi Naik, Siobán B Keel, et al.
Hepatology (Baltimore, Md.)|July 28, 2023
Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyriaCynthia Levy, Amy K Dickey, Bruce Wang, et al.
Hepatology Communications|February 19, 2025
Liver involvement in a large cohort of patients with erythropoietic protoporphyria or X-linked protoporphyriaCynthia Levy, Hetanshi Naik, Jessica Overbey, et al.
Molecular Genetics and Metabolism|July 3, 2026
Accessibility and harmonization of biochemical tests for diagnosis and monitoring of Porphyrias in the United States: Recommendations by members of the American Porphyrias Expert Collaborative (APEX)Karl E Anderson, Robert J Desnick, Herbert L Bonkovsky, et al.
Blood Advances|December 3, 2024
Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab eraAyotola Fatola, Michael D Evans, Jenna Brown, et al.
Research and Practice in Thrombosis and Haemostasis|April 23, 2024
A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpuraMouhamed Yazan Abou-Ismail, Chong Zhang, Angela P Presson, et al.
Blood Advances|December 15, 2023
A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP RegistryMouhamed Yazan Abou-Ismail, Chong Zhang, Angela P Presson, et al.
Eclinicalmedicine|April 16, 2025
Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)Paul Coppo, Michael Bubenheim, Ygal Benhamou, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
American Journal of Hematology|September 23, 2023
Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance databaseNattawat Klomjit, Richard Evans, Thomas K Le, et al.
Platelets|November 29, 2017
Endothelial alterations in a canine model of immune thrombocytopeniaDana N LeVine, Rachel E Cianciolo, Keith E Linder, et al.
Journal of the American Academy of Dermatology|August 30, 2022
Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyriaAmy K Dickey, Hetanshi Naik, Siobán B Keel, et al.
Hepatology (Baltimore, Md.)|July 28, 2023
Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyriaCynthia Levy, Amy K Dickey, Bruce Wang, et al.
Hepatology Communications|February 19, 2025
Liver involvement in a large cohort of patients with erythropoietic protoporphyria or X-linked protoporphyriaCynthia Levy, Hetanshi Naik, Jessica Overbey, et al.
Molecular Genetics and Metabolism|July 3, 2026
Accessibility and harmonization of biochemical tests for diagnosis and monitoring of Porphyrias in the United States: Recommendations by members of the American Porphyrias Expert Collaborative (APEX)Karl E Anderson, Robert J Desnick, Herbert L Bonkovsky, et al.
Blood Advances|December 3, 2024
Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab eraAyotola Fatola, Michael D Evans, Jenna Brown, et al.
Research and Practice in Thrombosis and Haemostasis|April 23, 2024
A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpuraMouhamed Yazan Abou-Ismail, Chong Zhang, Angela P Presson, et al.
Blood Advances|December 15, 2023
A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP RegistryMouhamed Yazan Abou-Ismail, Chong Zhang, Angela P Presson, et al.
Eclinicalmedicine|April 16, 2025
Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)Paul Coppo, Michael Bubenheim, Ygal Benhamou, et al.
Pageof 2